Literature DB >> 7629887

Heterogeneity of human neuroblastoma cell lines in their proliferative responses to basic FGF, NGF, and EGF: correlation with expression of growth factors and growth factor receptors.

T Janet1, G Lüdecke, U Otten, K Unsicker.   

Abstract

Growth factors can induce both proliferation or differentiation of neuroblastoma (NB) cells through interaction with specific receptors. Using two automated colorimetric assays for determinations of cell numbers, the present study demonstrates that a) different NB and neuroepithelioma cell lines show distinct responses, both qualitatively and quantitatively, to basic FGF (bFGF), NGF, and EGF; b) even closely related NB cell lines (e.g., SK-N-SH, SH-SY5Y, and SHEP) do not respond uniformly to these factors; c) responses of the two neuroepithelioma cell lines employed (SK-N-MC and CHP-100) differ, but match those of certain NB cell lines; and d) two growth factors, bFGF and EGF, may both stimulate or inhibit proliferation, depending on the cell line studied. Specifically, IMR-32, SK-N-SH, and SH-SY5Y showed a mitogenic response to each growth factor. Maximal proliferative responses ranged from 204-355% as compared to controls (100%). GICAN was stimulated by NGF (199%), and SK-N-MC and NMB by EGF (282 and 140%, respectively), but other factors were ineffective. CHP-100 and GIMEN were inhibited by bFGF. NGF and EGF were not effective on CHP-100 cells, while EGF caused an arrest of mitogenic activity in GIMEN cells, and NGF stimulated their proliferation. Cell lines SHEP and LAN1 did not respond to any factor. To begin to analyze putative relationships of growth factor responsiveness and growth factor/growth factor receptor expressions, IMR-32, GIMEN, and LAN1 cell lines were studied for the presence of bFGF, NGF, FGF receptors (R)-1 (flg) and FGFR-4, trk, and low-affinity NGF receptor (p75) mRNAs.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7629887     DOI: 10.1002/jnr.490400602

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  10 in total

1.  An in vitro paradigm for diabetic cerebral oedema and its therapy: a critical role for taurine and water channels.

Authors:  Ildi H Koves; Vincenzo C Russo; Sandra Higgins; Avantika Mishra; James Pitt; Fergus J Cameron; George A Werther
Journal:  Neurochem Res       Date:  2011-09-21       Impact factor: 3.996

2.  Critical role of FLRT1 phosphorylation in the interdependent regulation of FLRT1 function and FGF receptor signalling.

Authors:  Lee M Wheldon; Bryan P Haines; Rajit Rajappa; Ivor Mason; Peter W Rigby; John K Heath
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

3.  Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines.

Authors:  C Missale; A Codignola; S Sigala; A Finardi; M Paez-Pereda; E Sher; P F Spano
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

4.  Low complex ganglioside expression characterizes human neuroblastoma cell lines.

Authors:  Simone Hettmer; Stephan Ladisch; Karen Kaucic
Journal:  Cancer Lett       Date:  2005-01-07       Impact factor: 8.679

5.  A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.

Authors:  Sarah B Whittle; Sahily Reyes; Melissa Du; Monica Gireud; Linna Zhang; Sarah E Woodfield; Michael Ittmann; Michael E Scheurer; Andrew J Bean; Peter E Zage
Journal:  J Pediatr Hematol Oncol       Date:  2016-03       Impact factor: 1.289

6.  The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.

Authors:  Kathy Scorsone; Linna Zhang; Sarah E Woodfield; John Hicks; Peter E Zage
Journal:  Invest New Drugs       Date:  2014-05-16       Impact factor: 3.850

7.  Neurological morphofunctional differentiation induced by REAC technology in PC12. A neuro protective model for Parkinson's disease.

Authors:  Margherita Maioli; Salvatore Rinaldi; Rossana Migheli; Gianfranco Pigliaru; Gaia Rocchitta; Sara Santaniello; Valentina Basoli; Alessandro Castagna; Vania Fontani; Carlo Ventura; Pier Andrea Serra
Journal:  Sci Rep       Date:  2015-05-15       Impact factor: 4.379

8.  Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.

Authors:  Divya Subramonian; Nikki Phanhthilath; Hannah Rinehardt; Sean Flynn; Yuchen Huo; Jing Zhang; Karen Messer; Qianxing Mo; Shixia Huang; Jacqueline Lesperance; Peter E Zage
Journal:  Br J Cancer       Date:  2020-05-27       Impact factor: 7.640

9.  NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers.

Authors:  Atsushi Takatori; Md Shamim Hossain; Atsushi Ogura; Jesmin Akter; Yohko Nakamura; Akira Nakagawara
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

10.  REN: a novel, developmentally regulated gene that promotes neural cell differentiation.

Authors:  Rita Gallo; Francesca Zazzeroni; Edoardo Alesse; Claudia Mincione; Ugo Borello; Pasquale Buanne; Roberta D'Eugenio; Andrew R Mackay; Beatrice Argenti; Roberto Gradini; Matteo A Russo; Marella Maroder; Giulio Cossu; Luigi Frati; Isabella Screpanti; Alberto Gulino
Journal:  J Cell Biol       Date:  2002-08-19       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.